Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants




Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.
CLICK TO VIEW THE SOURCE MATERIAL


Post a comment


You must sign in before you can post comments. If you are experiencing issues with your account please e-mail abuse@unionleader.com.